17038-83-4

Basic information

• Product Name: 1-Acetyl-4-oxonipecotic acid methyl ester
• Synonyms: 1-Acetyl-4-oxo-3-piperidinecarboxylic acid methyl ester;1-Acetyl-4-oxonipecotic acid methyl ester;Methyl 1-acetyl-4-oxopiperidine-3-carboxylate
• CAS NO: 17038-83-4
• Molecular Formula: C9H13NO4
• Molecular Weight: 199.20382
• Mol File: 17038-83-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 287℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.223
• CAS DataBase Reference: 1-Acetyl-4-oxonipecotic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Acetyl-4-oxonipecotic acid methyl ester(17038-83-4)
• EPA Substance Registry System: 1-Acetyl-4-oxonipecotic acid methyl ester(17038-83-4)

Safety Data

• Hazardous Substances Data: 17038-83-4(Hazardous Substances Data)

Usage

Chemical class

Alpha amino acid esters

Derivation

Condensation of N-acetyl-4-aminobutyric acid with acetic anhydride

Common use

Precursor in the synthesis of pharmaceutical drugs and biologically active compounds

Potential applications

Treatment of neurological disorders

Role in research

Building block for synthesis of novel compounds with therapeutic properties

Utility in understanding

Mechanisms of action and metabolism of related compounds in biological systems

Upstream product

• 108-24-7 acetic anhydride 
• 108554-34-3 methyl 4-oxonipecotate 
• 71486-53-8 methyl 4-oxo-3-piperidinecarboxylate hydrochloride 

Downstream Products

• 1226887-44-0 1-(4-hydroxy-2-(4-(oxazol-5-yl)phenylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)ethanone 

Relevant articles and documents

MODULATORS OF AMYLOID BETA.

The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.